
Epizyme EPZM
Quarterly report 2022-Q2
added 08-09-2022
Epizyme Cash Conversion Cycle 2011-2025 | EPZM
Annual Cash Conversion Cycle Epizyme
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -308 | 102 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 102 | -308 | -103 |
Quarterly Cash Conversion Cycle Epizyme
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -85.6 | -249 | - | -241 | -153 | -3.96 | -213 | -200 | -326 | -1.22 K | 54.5 | 41 | 39.7 | 131 | 189 | 153 | 153 | - | - | 3.49 | 3.49 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 189 | -1.22 K | -107 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
31.5 | $ 4.72 | 0.96 % | $ 783 M | ||
|
Aclaris Therapeutics
ACRS
|
-881 | $ 3.32 | -1.19 % | $ 257 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
166 | $ 25.26 | -2.47 % | $ 1.22 B | ||
|
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
25 | - | -15.15 % | $ 60.3 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-2.85 K | - | -11.43 % | $ 502 K | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | ||
|
Albireo Pharma
ALBO
|
-1.55 K | - | -0.23 % | $ 916 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M | ||
|
Aptorum Group Limited
APM
|
-400 | $ 1.31 | -1.88 % | $ 7.14 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | ||
|
AstraZeneca PLC
AZN
|
-58 | $ 89.77 | -0.57 % | $ 96.9 B | ||
|
Anika Therapeutics
ANIK
|
270 | $ 9.59 | 1.05 % | $ 141 M | ||
|
Brickell Biotech
BBI
|
149 | - | -5.38 % | $ 6.06 M | ||
|
BeiGene, Ltd.
BGNE
|
49.5 | - | 0.49 % | $ 251 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
6.09 | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
214 | - | -7.31 % | $ 87 M | ||
|
Biogen
BIIB
|
387 | $ 174.05 | 0.9 % | $ 25.3 B | ||
|
Aytu BioScience
AYTU
|
174 | $ 2.33 | 2.08 % | $ 14.6 M | ||
|
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B | ||
|
Baudax Bio
BXRX
|
-14.3 | - | 0.59 % | $ 63 K | ||
|
Benitec Biopharma
BNTC
|
141 | $ 12.26 | -5.4 % | $ 505 M | ||
|
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - | ||
|
ChromaDex Corporation
CDXC
|
23.8 | - | -0.88 % | $ 598 M | ||
|
Axon Enterprise
AXON
|
86.2 | $ 570.12 | -1.88 % | $ 43.2 B | ||
|
Catalyst Biosciences
CBIO
|
391 | $ 14.66 | -4.25 % | $ 965 M | ||
|
Caladrius Biosciences
CLBS
|
164 | - | -16.75 % | $ 25.8 M | ||
|
Clovis Oncology
CLVS
|
65.5 | - | -7.23 % | $ 13 M | ||
|
Celldex Therapeutics
CLDX
|
-6.08 K | $ 27.54 | -1.43 % | $ 1.77 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
-101 | - | - | $ 2.18 B | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
209 | $ 11.3 | -1.22 % | $ 731 M | ||
|
Cerus Corporation
CERS
|
59.2 | $ 2.15 | -0.23 % | $ 397 M | ||
|
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K |